Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.57 |
| ▸ | CA2 | P00918 | 8/20 | 0.57 |
| ▸ | CA9 | Q16790 | 6/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27450675 | 0.83 | CYP1A2 (0.54) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL9464709 | 0.82 | CA2 (0.45) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL294031 | 0.82 | CYP1A2 (0.52) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL23722235 | 0.81 | PTGES2 (0.58) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL30647960 | 0.81 | PTGES2 (0.58) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL11692490 | 0.81 | CA2 (0.44) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL17374931 | 0.81 | CA2 (0.48) | CA1CA2CA9CA5ACYP2A6 | |
| SCHEMBL12230567 | 0.80 | CYP1A2 (0.50) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL171848 | 0.80 | CYP1A2 (0.55) | LMNACYP1A2CYP2A6HTR2AHTR2C | |
| SCHEMBL2374771 | 0.80 | CYP1A2 (0.50) | CA1CA2CA9LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021114313-A1 | ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
| EP-2513092-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073114-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RRM2B, POLR2A, RRM2 | CA1 4778/4885CA2 4785/4885CA9 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.